Currently out of the existing stock ratings of Bing Zhao, 2 are a BUY (100%).
Analyst Bing Zhao, currently employed at CHINA RENAISSANCE, has had 100% of price targets met with an average potential upside of 88.55%, reached in 201 days on average. Previously, Bing Zhao worked at STIFEL.
Bing Zhao has documented 4 price targets and ratings displayed on 1 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on IMAB, I-Mab at 08-Jul-2021.
Analyst best performing recommendations are on IMAB (I-MAB).
The best stock recommendation documented was for IMAB (I-MAB) on 2/11/2020. The price target of $17.93 was fulfilled within 78 days with a profit of $6.75 (60.38%), with a performance score of 7.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 09-Sep-2025
$9
$9
1 years 29 days ago
(24-Oct-2025)
0/3 (0%)
$4.78 (113.27%)
Buy Since 02-Nov-2021
$6
$6
1 years 2 months 14 days ago
(08-Sep-2025)
4/10 (40%)
$1.73 (40.52%)
44
Buy Since 09-Jul-2025
$7
$7
1 years 3 months 1 days ago
(21-Aug-2025)
0/2 (0%)
$2.29 (48.62%)
Buy Since 07-Dec-2020
$7
1 years 4 months 26 days ago
(27-Jun-2025)
2/7 (28.57%)
$4.63 (195.36%)
59
Buy Since 25-Feb-2021
$8
$10
2 years 2 months 6 days ago
(16-Sep-2024)
3/5 (60%)
$6.94 (654.72%)
373
What Year was the first public recommendation made by Bing Zhao?